News

The drug is approved for these children who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Earlier in 2008, the FDA approved Promacta for use in

The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson’s disease. "This recent patent award will provide robust protection for MLR-1019

In addition, the company has received a notice of allowance of Canada Patent 2,665,783, which covers processes for making a broad range of amphoteric liposomes, including the SMARTICLES

The product candidate is developed for the indications of refractory and tophaceous gout, which result from elevated levels of uric acid within the body that cause debilitating pain

OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated

Cyclosporine A, when administered systemically (Sandimmune, Neoral), is an effective treatment for psoriasis, atopic dermatitis, pemphigus vulgaris and other severe inflammatory dermatoses. Dr. Daniel Teper, the CEO of

The trial, being carrying out at MAC Clinical Research in Manchester, UK, will evaluate the safety and efficacy of oral ZPL-389 in the treatment of inflammatory skin diseases,

Results from the trial show that d-Methadone was generally well tolerated and a maximum tolerated dose (MTD) was achieved. The company said that the planned multiple ascending dose

The trial is being carried out at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, US.